In the continuous evolution of healthcare, Contract Research Organizations (CROs) play a crucial role, with Altasciences at the forefront. Led by CEO Chris Perkin since 2010, Altasciences has pioneered a transformative approach to outsourcing in drug development. The organization provides end-to-end solutions, encompassing preclinical research, early-phase clinical trials, and more. With nine facilities across Canada and the U.S. and a strategic presence in the UK, Altasciences specializes in seamless, early-phase drug development. Their comprehensive services, including drug formulation, manufacturing, bioanalysis, and full CRO support, make Altasciences a trusted, all-encompassing partner for pharmaceutical sponsors.
With nearly 50 years in the drug development industry, Chris began his career in 1975 as a preclinical study director in England. Over the years, he progressed through various leadership roles in the pharmaceutical and CRO sectors, eventually becoming the CEO of Altasciences in 2010. Chris’s inspiration for joining Altasciences stemmed from a desire to streamline early-phase drug development, creating an integrated solution. Under his leadership, Altasciences has pioneered proactive drug development, offering comprehensive services across preclinical and clinical phases. The mission is to expedite the drug development process, delivering faster, more efficient solutions while upholding rigorous quality and compliance standards.
Altasciences is committed to establishing itself as the premier one-stop solution for early-phase drug development. The company prioritizes the development of robust, long-term relationships with clients, ensuring a smooth and comprehensive experience while maximizing the value of its services. Additionally, Altasciences remains focused on nurturing strategic partnerships, addressing client needs, and continually enhancing its offerings. In the near future, the company intends to expand its preclinical facilities and bioanalytical laboratories, while also increasing its footprint in Europe. Sustainability is a fundamental principle at Altasciences, reflected in its ongoing efforts to reduce emissions, promote diversity, and adhere to Environmental, Social, and Governance (ESG) standards. These core values are integral to both the company’s current operations and long-term goals.
Celebrated by Insights Care as Most Innovative CRO Pioneering Excellence in Europe, AltaSciences remain steadfast in its mission to streamline the drug development process, ensuring faster, more efficient outcomes for its clients.
